Adverse Reactions to Antimicrobial and Antineoplastic Agents

Author(s):  
Harry F. Dowling
2020 ◽  
Vol 14 ◽  
Author(s):  
Bruno Ferreira Amorim ◽  
Simone Yuriko Kameo ◽  
Glebson Moura Silva ◽  
Giliane Leite Hardman ◽  
Jessica Dos Santos Costa ◽  
...  

Objetivo: descrever o manejo do extravasamento de trastuzumabe emtansina em uma paciente com carcinoma ductal invasivo da mama. Método: trata-se de um estudo qualitativo, descritivo, do tipo relato de caso clínico, num ambulatório de tratamento de câncer. Coletaram-se os dados por meio de informações nos prontuários e imagens realizadas pela equipe multiprofissional. Consolidaram-se as informações e os dados foram interpretados e analisados após a descrição das informações. Resultados: manejou-se o extravasamento com base no protocolo institucional com a paciente recebendo alta no mesmo dia, e esta evoluiu com o surgimento de uma reação inflamatória intensa com a presença de edema, bolhas e vesículas após o episódio. Ocorreu-se a recuperação total após 54 dias do ocorrido. Conclusão: concluiu-se que é necessária uma qualificação contínua da equipe, com base em evidências científicas atualizadas, para que ela possa intervir em situações de extravasamento quimioterápico de forma adequada. Descritores: Tratamento Farmacológico; Extravasamento de Materiais Terapêuticos e Diagnósticos; Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Antineoplásicos; Neoplasias da Mama; Oncologia.AbstractObjective: to describe the management of trastuzumab emtansine extravasation in a patient with invasive ductal breast carcinoma. Method: this is a qualitative, descriptive, clinical case report type, in a cancer treatment clinic. Data was collected through information in the medical records and images taken by the multi-professional team. The information was consolidated and the data were interpreted and analyzed after the description of the information. Results: extravasation was managed based on the institutional protocol with the patient being discharged on the same day, and this evolved with the appearance of an intense inflammatory reaction with the presence of edema, blisters and vesicles after the episode. Full recovery occurred 54 days after the event. Conclusion: it was concluded that a continuous qualification of the team is necessary, based on updated scientific evidence, so that it can intervene in situations of chemotherapy extravasation in an appropriate way. Descriptors: Drug Therapy; Extravasation of Diagnostic and Therapeutic Materials; Drug-Related Side Effects and Adverse Reactions; Antineoplastic Agents; Breast Neoplasms; Medical Oncology. ResumenObjetivo: describir el manejo de la extravasación de trastuzumab emtansine en una paciente con carcinoma ductal de mama invasivo. Método: este es un tipo de informe de caso clínico cualitativo, descriptivo, en una clínica de tratamiento del cáncer. Los datos fueron recolectados a través de información en los registros médicos e imágenes tomadas por el equipo multiprofesional. La información se consolidó y los datos se interpretaron y analizaron después de la descripción de las informaciones. Resultados: la extravasación se manejó según el protocolo institucional con el alta del paciente el mismo día, que evolucionó con la aparición de una reacción inflamatoria intensa con la presencia de edema, ampollas y vesículas después del episodio. La recuperación completa ocurrió 54 días después del evento. Conclusión: se concluyó que es necesaria una calificación continua del equipo, basada en evidencia científica actualizada, para que pueda intervenir en situaciones de extravasación de quimioterapia de manera adecuada. Descriptores: Quimioterapia; Extravasación de Materiales Terapéuticos y Diagnósticos; Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos; Antineoplásicos; Neoplasias de la Mama; Oncología Médica.


2010 ◽  
Vol 44 (6) ◽  
pp. 10-11
Author(s):  
JENNIE SMITH
Keyword(s):  

2007 ◽  
Vol 40 (7) ◽  
pp. 18-19
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  

2015 ◽  
Vol 20 (3) ◽  
pp. 155-166 ◽  
Author(s):  
Larissa J. Maier ◽  
Michael P. Schaub

Abstract. Pharmacological neuroenhancement, defined as the misuse of prescription drugs, illicit drugs, or alcohol for the purpose of enhancing cognition, mood, or prosocial behavior, is not widespread in Europe – nevertheless, it does occur. Thus far, no drug has been proven as safe and effective for cognitive enhancement in otherwise healthy individuals. European studies have investigated the misuse of prescription and illicit stimulants to increase cognitive performance as well as the use of tranquilizers, alcohol, and cannabis to cope with stress related to work or education. Young people in educational settings report pharmacological neuroenhancement more frequently than those in other settings. Although the regular use of drugs for neuroenhancement is not common in Europe, the irregular and low-dose usage of neuroenhancers might cause adverse reactions. Previous studies have revealed that obtaining adequate amounts of sleep and using successful learning techniques effectively improve mental performance, whereas pharmacological neuroenhancement is associated with ambiguous effects. Therefore, non-substance-related alternatives should be promoted to cope with stressful situations. This paper reviews the recent research on pharmacological neuroenhancement in Europe, develops a clear definition of the substances used, and formulates recommendations for practitioners regarding how to react to requests for neuroenhancement drug prescriptions. We conclude that monitoring the future development of pharmacological neuroenhancement in Europe is important to provide effective preventive measures when required. Furthermore, substance use to cope with stress related to work or education should be studied in depth because it is likely more prevalent and dangerous than direct neuroenhancement.


JAMA ◽  
1966 ◽  
Vol 198 (2) ◽  
pp. 173-174 ◽  
Author(s):  
G. Westerman
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document